Introduction
Mark P. Goldberg, MD I n 10 years after the US Food and Drug Administration's approval of intravenous tissue plasminogen activator (tPA) for acute ischemic stroke, tPA has had only a modest impact in the overall burden of disease. Current estimates suggest that about 2% to 8% of US ischemic stroke patients receive tPA, 1 and that continuing improvement of in-hospital care might not increase this proportion much beyond 20%. 2 There remains an urgent need for additional therapeutic approaches to acute ischemic stroke. Neuroprotective drug strategies offer the promise of limiting infarct tissue damage without increasing hemorrhage risk. Despite an extensive literature showing neuroprotective drug actions in reducing infarct size in rodent ischemia models, efficacy has not been confirmed in large multicenter clinical trials. 3, 4 This situation is not unique to neuroprotective agents because many promising recanalization approaches have also failed. For example, a large trial of the glycoprotein IIb/IIIa inhibitor, abciximab, administered within 5 hours of symptom onset (or 3 hours after awakening with stroke) was recently terminated because of concerns of increased risk of intracranial hemorrhage in the treatment group. 5 The defibrinogenating agent, ancrod, did not improve stroke outcome when administered within 6 hours of symptom onset (ESTAT study 5 ) although it was found effective within 3 hours of onset in a previously reported trial with otherwise similar design (STAT study 6 ). The parallel experience with clinical trials of tPA and ancrod serves to highlight the importance of early stroke recognition and rapid drug administration. No intravenously administered recanalization agent has been proven effective beyond 3 hours after onset, and no neuroprotective agent has even been tested within this time window.
Considering the number of negative studies, and the persisting difficulties of very early patient recruitment, industry and public sponsors are understandably wary of the committment required for new acute intervention trials. The NIH-funded NINDS tPA trial 7 cost more than $18 million (scaled to 2004 US dollars) 8 and current industry-sponsored stroke trials are likely much more expensive. What are the prospects for future development of effective stroke therapies? This Princeton session examined the challenges from two perspectives: improving therapeutic options and improving trial methodologies.
First, new therapeutic directions in neuroprotection may offer improved clinical efficacy, hopefully also extending the time window for treatment initiation. Drs Hemmen and Lyden described clinical experience and rationale for induced hypothermia in ischemic stroke. Hypothermia provides robust protection in many animal stroke models, most likely by action on multiple injury mechanisms in parallel. Advances in cooling technology offer new opportunities for experimental interventions. In the session discussion, Dr Ginsberg briefly reviewed experience with high-dose human albumin therapy in acute stroke, another promising approach with multiple potential actions. 9 Dr Zivin described the preclinical experience and initial clinical trials of NXY-059, a free-radical spin trapping agent with cytoprotective actions not only for neurons, but potentially also for glial and endothelial cells. The Stroke-Acute Ischemic NXY Treatment (SAINT) I clinical trial showed a modest but statistically significant improvement in clinical outcome scores and a possible reduction in risk of hemorrhagic transformation. 10 However, preliminary results of the second major clinical trial, SAINT II, have been announced several months after the Princeton Conference. NXY-059 did not provide a therapeutic benefit for stroke outcome or hemorrhage rate, and clinical development of this agent has been halted. 5 The implications of these results will await presentation of the clinical trial data. Dr Zivin also presented results of an important new secondary stroke prevention study, Stroke Prevention with Aggressive Reduction in Cholesterol Levels (SPARCL), released just before the Princeton Conference.
A second approach to acute intervention trials is to seek more cost-effective clinical study methodologies. Optimal design of preclinical and clinical trials has been the subject of an ongoing bi-annual conference, the Stroke Therapy Academic Industry Roundtable. [11] [12] [13] [14] For this Princeton session, the organizers requested ideas from other clinical disciplines. Dr Howard described several advanced biostatistical approaches to reduction of sample size. New statistical approaches may reduce patient numbers in dose-finding studies, adaptively scale the sample size in phase III trials, or increase the sensitivity of conventional stroke outcome measures. As noted by Dr Howard, and also in the session discussion, some methods are not equally applicable to the stroke situation, and some come with costs of increasing statistical assumptions or uncertainty in trial planning. Acute intervention trials for stroke are undeniably costly, but it is important to consider these costs in the context of the much larger personal and societal economic burden of the disease itself. A recent analysis compared the costs and public heath benefits of all 28 phase III clinical trials supported by the NINDS between 1977 and 2000. 8 The total cost of funding these trials was $335 million (measured in 2004 dollars). The economic benefit was estimated at over $15 billion over 10 years. We can build better clinical stroke trials; we can't afford not to.
